Answers are grounded in this paper and cite their sources.
Background and objectivePostpartum hemorrhage (PPH) is an important cause of maternal morbidity.Hemorrhage-related outcomes among women receiving different prophylactic uterotonic regimens during cesarean delivery warrant investigation in routine clinical settings.The objective of this study is to describe and compare hemorrhagerelated maternal outcomes among women receiving oxytocin, misoprostol, or carbetocin prophylaxis during cesarean delivery. MethodsThis single-center prospective observational study included 150 women undergoing cesarean delivery at Sri Krishna Medical College and Hospital, Muzaffarpur, India.Participants were recruited using predefined quotas of 50 women per prophylactic uterotonic group.Medication selection was clinician-directed without randomization.For the revised exploratory analysis, PPH was classified using estimated cumulative blood loss ≥500 mL within 24 hours after delivery, irrespective of cause.Other outcomes included estimated blood-loss categories, postoperative hemoglobin concentrations, additional oxytocin administration, blood transfusion, surgical interventions, and adverse events.Analyses were exploratory and unadjusted. ResultsBlood-loss-defined PPH occurred in four women (8%) receiving carbetocin, eight (16%) receiving oxytocin, and 31 (62%) receiving misoprostol.Estimated blood loss exceeding 1,000 mL occurred in one (2%), four (8%), and 10 (20%) women, respectively.Additional oxytocin was administered to seven (14%), 12 (24%), and 25 (50%) women, while blood transfusion was recorded in four (8%), 10 (20%), and 17 (34%) women, respectively.The overall association between prophylactic regimen and blood-loss-defined PPH was statistically significant (χ² = 41.53,p < 0.001).These findings were unadjusted and subject to potential confounding. ConclusionBlood-loss-defined PPH and other recorded hemorrhage-related outcomes varied across the three clinicianselected prophylactic regimens.These exploratory findings do not establish causal treatment superiority because of the nonrandomized design, potential confounding, and limitations of retrospective outcome classification.Further studies with prespecified outcomes and appropriate adjustment for baseline differences are required.
No takes yet. Share an insight, caveat, or question.
. et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: